Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9 USD | +1.43% | +15.99% | +9.54% |
Apr. 25 | Transcript : HOOKIPA Pharma Inc. - Special Call | |
Apr. 25 | HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.54% | 87.8M | |
+34.00% | 704B | |
+27.80% | 577B | |
-7.75% | 348B | |
+18.53% | 327B | |
+4.95% | 288B | |
+15.17% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-4.89% | 147B |
- Stock Market
- Equities
- HOOK Stock
- News HOOKIPA Pharma Inc.
- HOOKIPA Pharma : Morgan Stanley Adjusts Price Target on HOOKIPA Pharma to $18 From $19, Maintains Overweight Rating